Literature DB >> 10840210

Toxic shock syndrome.

.   

Abstract

Toxic shock syndrome (TSS) is an acute febrile illness accompanied by watery diarrhea, sunburn rash, vomiting, hypotension, and multiple organ involvement. When it was initially recognized 20 years ago, TSS was primarily associated with menstruation. Since then, the frequency of menstrual TSS has decreased dramatically. Staphylococcus aureus is the cause of menstrual TSS and is also responsible for about half of all cases of nonmenstrual TSS. Since the late 1980s, Streptococcus pyogenes has been shown to cause a nonmenstrual TSS-like illness, with a higher mortality rate. The mechanism of TSS is attributable to bacterial endotoxins that impede the body's immune system and cause the release of cytokines, which are responsible for the clinical manifestations of the disease. Early recognition and treatment of TSS are important factors in improving patient survival. Patients should be treated with parenteral antibiotics that are highly effective against staphylococci and streptococci. They should also receive fluid resuscitation and vasopressors. Some patients require intubation, dialysis, or immunoglobulin therapy.

Entities:  

Year:  2000        PMID: 10840210     DOI: 10.1016/s1068-607x(00)00027-5

Source DB:  PubMed          Journal:  Prim Care Update Ob Gyns        ISSN: 1068-607X


  3 in total

1.  [Toxic shock syndrome (TSS) after a postsurgery knee infection].

Authors:  M de Jesus Pereira; K Jäckle
Journal:  Orthopade       Date:  2010-11       Impact factor: 1.087

2.  Norepinephrine potentiates proinflammatory responses of human vaginal epithelial cells.

Authors:  Amanda J Brosnahan; Lucy Vulchanova; Samantha R Witta; Yuying Dai; Bryan J Jones; David R Brown
Journal:  J Neuroimmunol       Date:  2013-04-06       Impact factor: 3.478

3.  Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome.

Authors:  Rita Kansal; Catherine Davis; Melanie Hansmann; Jon Seymour; Jeffrey Parsonnet; Paul Modern; Steve Gilbert; Malak Kotb
Journal:  J Clin Immunol       Date:  2007-03-06       Impact factor: 8.542

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.